{
    "title": "New class of cancer drugs down, not out, after Roche trial setback - analysts",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10806759/New-class-cancer-drugs-not-Roche-trial-setback--analysts.html",
    "date": "2022-05-11",
    "keywords": [
        "cancer",
        "roche",
        "trial",
        "wednesday",
        "class",
        "lung",
        "combination",
        "tecentriq",
        "study",
        "grover",
        "field",
        "setback",
        "oncology",
        "drug",
        "tiragolumab",
        "disease",
        "progression",
        "immunotherapy",
        "news",
        "march",
        "form",
        "pdl1",
        "research",
        "market",
        "analyst",
        "note",
        "immunooncology",
        "benefit",
        "checkpoint",
        "london",
        "blow",
        "shadow",
        "end",
        "road",
        "analysis",
        "nonsmallcell",
        "nsclc",
        "versus",
        "standard",
        "drugmaker",
        "rarer",
        "likelihood",
        "success",
        "antitigit",
        "flurry",
        "deal",
        "activity",
        "co",
        "gsk",
        "piece",
        "protein",
        "system",
        "detection",
        "day",
        "failure",
        "sector",
        "truist",
        "year",
        "difference",
        "survival",
        "precedence",
        "chemotherapy",
        "pd1",
        "hope",
        "pdl1pd1",
        "set",
        "sting",
        "string",
        "capital",
        "coadministration",
        "result",
        "doubt",
        "efficacy",
        "drugconstruct",
        "way",
        "plan",
        "chance",
        "reporting",
        "twitter",
        "josephine",
        "mason",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}